Table 1.

Patient demographics and disease characteristics at baseline

CharacteristicAll treated patients (n = 159), n (%)
Age  
 Median, y (range) 60 (33-71) 
 ≥65 y 45 (28) 
Male 106 (67) 
ECOG PS  
 0 110 (69) 
 1 49 (31) 
Histology  
 CLL 146 (92) 
 SLL 13 (8) 
Rai stage  
 0/I/II 113 (71) 
 III/IV 44 (28) 
 Missing 2 (1) 
Bulky disease (cm)  
 ≥5 48 (30) 
 ≥10 5 (3) 
Cytopenia at baseline  
 Any cytopenia 54 (34) 
 Hemoglobin ≤11 g/dL 37 (23) 
 Platelet count ≤100 × 109/L 21 (13) 
 ANC ≤1.5 × 109/L 13 (8) 
Hierarchical cytogenetics (FISH) classification*  
 Del(17p) 20 (13) 
 Del(11q) 28 (18) 
 Trisomy 12 23 (14) 
 Normal 33 (21) 
 Del(13q) 54 (34) 
 Unknown 1 (1) 
Mutated TP53  
 Yes 16 (10) 
 No 142 (89) 
 Unknown 1 (1) 
Del(17p) or mutated TP53  
 Yes 27 (17) 
 No 129 (81) 
 Unknown 3 (2) 
IGHV gene mutation status  
 Unmutated 89 (56) 
 Mutated 66 (42) 
 Unknown 4 (3) 
Complex karyotype  
 Yes 31 (19) 
 No 102 (64) 
 Unknown 26 (16) 
CharacteristicAll treated patients (n = 159), n (%)
Age  
 Median, y (range) 60 (33-71) 
 ≥65 y 45 (28) 
Male 106 (67) 
ECOG PS  
 0 110 (69) 
 1 49 (31) 
Histology  
 CLL 146 (92) 
 SLL 13 (8) 
Rai stage  
 0/I/II 113 (71) 
 III/IV 44 (28) 
 Missing 2 (1) 
Bulky disease (cm)  
 ≥5 48 (30) 
 ≥10 5 (3) 
Cytopenia at baseline  
 Any cytopenia 54 (34) 
 Hemoglobin ≤11 g/dL 37 (23) 
 Platelet count ≤100 × 109/L 21 (13) 
 ANC ≤1.5 × 109/L 13 (8) 
Hierarchical cytogenetics (FISH) classification*  
 Del(17p) 20 (13) 
 Del(11q) 28 (18) 
 Trisomy 12 23 (14) 
 Normal 33 (21) 
 Del(13q) 54 (34) 
 Unknown 1 (1) 
Mutated TP53  
 Yes 16 (10) 
 No 142 (89) 
 Unknown 1 (1) 
Del(17p) or mutated TP53  
 Yes 27 (17) 
 No 129 (81) 
 Unknown 3 (2) 
IGHV gene mutation status  
 Unmutated 89 (56) 
 Mutated 66 (42) 
 Unknown 4 (3) 
Complex karyotype  
 Yes 31 (19) 
 No 102 (64) 
 Unknown 26 (16) 

ANC, absolute neutrophil count; ECOG PS, Eastern Cooperative Oncology Group performance status; FISH, fluorescence in situ hybridization; MRD, minimal residual disease.

*

Per Döhner hierarchy.

Defined as ≥3 abnormalities by CpG-stimulated cytogenetics.

Close Modal

or Create an Account

Close Modal
Close Modal